Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Novartis : to Invest More Than $100 Million to Research, Develop Antimalarials

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/17/2018 | 07:52am CEST

By Pietro Lombardi

Novartis AG (NOVN.EB) said Tuesday that it will invest more than $100 million in the next five years in the research and development of the next-generation antimalarials.

The investment will focus on treatments to tackle resistance to antimalarials currently in use.

"Resistance to treatment presents the biggest threat to the incredible progress that has been made in the fight against malaria in the past 20 years. We cannot afford to wait; this is why we are committing to advance the research and development of next-generation treatments," said Chief Executive Vas Narasimhan.

The company's also said it will work to expand access to pediatric antimalarials and will help implement programs to reinforce health-care systems in four sub-Saharan countries.

Write to Pietro Lombardi at [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
07/16NOVARTIS : Democrats report on Novartis, Cohen inquiry
AQ
07/14NOVARTIS : Michael Cohen contacts were more extensive than previously disclosed
AQ
07/13NOVARTIS : Played Down Ties to Trump Lawyer Michael Cohen, Report Says
DJ
07/13NOVARTIS : disputes U.S. senators' report on Cohen contract
RE
07/13NOVARTIS AG : half-yearly earnings release
07/13NOVARTIS : to Drop Anti-Infectives Research Programs and Lay Off 140
AQ
07/12NOVARTIS : Findings from Novartis Yields New Findings on Pharmaceutical Research..
AQ
07/12NOVARTIS : Shares Lifted by Prospect of Gilenya Exclusivity in US -- Update
DJ
07/12NOVARTIS : Patent Issued for Systems and Methods for Subretinal Delivery of Ther..
AQ
07/12NOVARTIS : Patent Issued for Optical Fiber Coupling Reliability (USPTO 10012800)
AQ
More news
News from SeekingAlpha
07/16DIVIDEND SENSEI'S PORTFOLIO UPDATE 4 : The 3 Essential Things All Investors Need.. 
07/16CVS responds to Trump Administration's request for info on now to lower drug .. 
07/15BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Cytodyn's Acquisition, Novartis Exits Ant.. 
07/15WEEK IN REVIEW : Tasly Biopharma Completes Pre-IPO Round At $1.9 Billion Valuati.. 
07/13ResTORbio - Leading The Charge Against Aging Related Diseases 
Financials ($)
Sales 2018 52 100 M
EBIT 2018 12 767 M
Net income 2018 9 303 M
Debt 2018 13 415 M
Yield 2018 3,73%
P/E ratio 2018 16,22
P/E ratio 2019 19,44
EV / Sales 2018 4,12x
EV / Sales 2019 3,97x
Capitalization 201 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 89,6 $
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS-4.54%201 464
JOHNSON & JOHNSON-9.87%337 763
PFIZER3.62%219 534
ROCHE HOLDING LTD.-5.78%201 132
MERCK AND COMPANY11.23%169 193
AMGEN12.66%129 635